title: Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population.
abstract: BACKGROUND
  To investigate the relationship between two common variants (Ser217 and Ala541) of the HPC2/ELAC2 gene and prostate cancer risk in a Japanese population, we performed a case-control study.
  
  
  METHODS
  Cases and controls consisted of 81 prostate cancer patients with a family history and 106 controls. Ser217 and Ala541 polymorphisms were analyzed by the restriction fragment length polymorphism method.
  
  
  RESULTS
  In controls, 94.5% and 100.0% had wild-type Ser217Ser and Ala541Ala genotypes, respectively. 5.7% of the controls had the Leu217 genotype. No Thr541 genotype was observed in the controls. 92.6% and 97.5% of the cases had the Ser217Ser and Ala541Ala genotypes. No significant differences were observed in the genotypic frequencies between controls and cases. We stratified prostate cancer cases according to the pathological grade (low- or high-grade) or the clinical stage (localized or metastatic). There was no statistical difference between the genotypic frequencies between the groups.
  
  
  CONCLUSIONS
  The present study suggested that the common variants in the HPC2/ELAC2 gene play a limited role in the risk of prostate cancer in the Japanese population.
authors.affiliation: Department of Urology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, Japan 371-8511. kazu@showa.gunma-u.ac.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Suzuki
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Ohtake
authors.forename: Seiji
authors.initials: S
authors.lastname: Nakata
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Takei
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsui
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Ono
authors.forename: Haruki
authors.initials: H
authors.lastname: Nakazato
authors.forename: Masaru
authors.initials: M
authors.lastname: Hasumi
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Koike
authors.forename: Kazuto
authors.initials: K
authors.lastname: Ito
authors.forename: Yoshitatsu
authors.initials: Y
authors.lastname: Fukabori
authors.forename: Kohei
authors.initials: K
authors.lastname: Kurokawa
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Yamanaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: C421605:ELAC2 protein, human; D009363:Neoplasm Proteins